A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

BACKGROUND: Treatment options are limited for participants with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that progressed after two or more prior therapies. Studies have shown that blockade of both lymphocyte-activation gene 3 (LAG-3) and programmed cell death protein 1 (PD-1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Garralda, E., Sukari, A., Lakhani, N.J., Patnaik, A., Lou, Y., Im, S.-A., Golan, T., Geva, R., Wermke, M., de Miguel, M., Palcza, J., Jha, S., Chaney, M., Abraham, A.K., Healy, J., Falchook, G.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832734/
https://www.ncbi.nlm.nih.gov/pubmed/36493599
http://dx.doi.org/10.1016/j.esmoop.2022.100639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832734/
https://www.ncbi.nlm.nih.gov/pubmed/36493599
http://dx.doi.org/10.1016/j.esmoop.2022.100639

Ejemplares similares